New drug cocktail targets tough esophageal cancer

NCT ID NCT07697040

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This trial tests a new drug called becotatug vedotin, given together with standard chemotherapy (cisplatin) and radiation, for people with a type of advanced esophageal cancer. The main goals are to find the safest dose and see how well the combination works. About 12 participants will take part in this early-stage study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Becotatug vedotin (a drug that targets cancer cells) combined with cisplatin (chemotherapy) and radiation therapy
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced esophageal cancer that hasn't spread widely.
What could go wrong
This is an early-phase trial with only 12 participants, so results may not apply to everyone. The drug combination may cause significant side effects, and it's too early to know if it works better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, 050000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.